Polypoidal choroidal vasculopathy: Evidence-Based Guidelines for Clinical Diagnosis and Treatment

Retina

Volumn 33, Issue 4, 2013, Pages 686-716

  Koh, Adrian H C ^a   Chen, Lee Jen ^b   Chen, Shih Jen ^c   Chen, Youxin ^d   Giridhar, Anantharam ^e   Iida, Tomohiro ^f,g   Kim, Hakyoung ^h   Yuk Yau Lai, Timothy ⁱ   Lee, Won Ki ^j   Li, Xiaoxin ^k   Han Lim, Tock ^l   Ruamviboonsuk, Paisan ^m   Sharma, Tarun ⁿ   Tang, Shibo ^o   Yuzawa, Mitsuko ^p  

^a Camden Medical Centre   (Singapore)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e Giridhar Eye Institute   (India)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^h Hallym University   (South Korea)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j The Catholic University of Korea   (South Korea)

^k PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^l TAN TOCK SENG HOSPITAL   (Singapore)

^m RAJAVITHI HOSPITAL   (Thailand)

ⁿ SANKARA NETHRALAYA   (India)

^o SUN YAT SEN UNIVERSITY   (China)

^p SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; EVIDENCE BASED PRACTICE; FLUORESCENCE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; MONOTHERAPY; OPHTHALMOSCOPY; PHOTODYNAMIC THERAPY; POLYP; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; CHOROID DISEASES; COLORING AGENTS; DATABASES, FACTUAL; EVIDENCE-BASED MEDICINE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYPS; PORPHYRINS;

EID: 84875933604     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182852446     Document Type: Review

References (178)

1. Yannuzzi LA.Idiopathic polypoidal choroidal vasculopathy.Macula Society Meeting, 1982, Miami, F.L.
2. Kleiner RC, Brucker AJ, Johnston RL.The posterior uveal bleeding syndrome.Retina 1990;10:9-17
3. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B.Idiopathic polypoidal choroidal vasculopathy (IPCV).Retina 1990;10: 1-8
4. Nakashizuka H, Mitsumata M, Okisaka S, et al.Clinicopathologic findings in polypoidal choroidal vasculopathy.Invest Ophthalmol Vis Sci 2008;49:4729-4737
5. Stern RM, Zakov ZN, Zegarra H, Gutman FA.Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women.Am J Ophthalmol 1985;100:560-569
6. Yannuzzi LA, Ciardella A, Spaide RF, et al.The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy.Arch Ophthalmol 1997;115:478-485
7. Chang YC, Wu WC.Polypoidal choroidal vasculopathy in Taiwanese patients.Ophthalmic Surg Lasers Imaging 2009; 40:576-581
8. Ciardella AP, Donsoff IM, Huang SJ, et al.Polypoidal choroidal vasculopathy.Surv Ophthalmol 2004;49:25-37
9. Lafaut BA, Leys AM, Snyers B, et al.Polypoidal choroidal vasculopathy in Caucasians.Graefes Arch Clin Exp Ophthalmol 2000;238:752-759
10. Uyama M, Wada M, Nagai Y, et al.Polypoidal choroidal vasculopathy: Natural history.Am J Ophthalmol 2002;133: 639-648
11. Okubo A, Arimura N, Abematsu N, Sakamoto T.Predictable signs of benign course of polypoidal choroidal vasculopathy: Based upon the long-Term observation of non-Treated eyes.Acta Ophthalmol 2010;88:e107-e114
12. Byeon SH, Lee SC, Oh HS, et al.Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients.Jpn J Ophthalmol 2008;52:57-62
13. Ciardella AP, Donsoff IM, Yannuzzi LA.Polypoidal choroidal vasculopathy.Ophthalmol Clin North Am 2002;15: 537-554
14. Yannuzzi LA, Wong DW, Sforzolini BS, et al.Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration.Arch Ophthalmol 1999;117:1503-1510
15. Ladas ID, Rouvas AA, Moschos MM, et al.Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population.Eye (Lond) 2004;18: 455-459
16. Scassellati-Sforzolini B, Mariotti C, Bryan R, et al.Polypoidal choroidal vasculopathy in Italy.Retina 2001;21:121-125
17. Lim TH, Laude A, Tan CS.Polypoidal choroidal vasculopathy: An angiographic discussion.Eye (Lond) 2010;24:483-490
18. Liu Y, Wen F, Huang S, et al.Subtype lesions of neovascular age-related macular degeneration in Chinese patients.Graefes Arch Clin Exp Ophthalmol 2007;245:1441-1445
19. Sho K, Takahashi K, Yamada H, et al.Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics.Arch Ophthalmol 2003;121:1392-1396
20. Maruko I, Iida T, Saito M, et al.Clinical characteristics of exudative age-related macular degeneration in Japanese patients.Am J Ophthalmol 2007;144:15-22
21. Takahashi K, Ishibashi T, Ogur Y, Yuzawa M.[Classification and diagnostic criteria of age-related macular degeneration].Nippon Ganka Gakkai Zasshi 2008;112:1076-1084
22. Okubo A, Sameshima M, Uemura A, et al.Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study.Br J Ophthalmol 2002; 86:1093-1098
23. Kuroiwa S, Tateiwa H, Hisatomi T, et al.Pathological features of surgically excised polypoidal choroidal vasculopathy membranes.Clin Experiment Ophthalmol 2004;32: 297-302
24. Terasaki H, Miyake Y, Suzuki T, et al.Polypoidal choroidal vasculopathy treated with macular translocation: Clinical pathological correlation.Br J Ophthalmol 2002;86:321-327
25. Uyama M, Matsubara T, Fukushima I, et al.Idiopathic polypoidal choroidal vasculopathy in Japanese patients.Arch Ophthalmol 1999;117:1035-1042
26. Sato T, Kishi S, Watanabe G, et al.Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy.Retina 2007;27:589-594
27. Anantharaman G, Ramkumar G, Gopalakrishnan M, Rajput A.Clinical features, management and visual outcome of polypoidal choroidal vasculopathy in Indian patients.Indian J Ophthalmol 2010;58:399-405
28. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin In Photodynamic Therapy (VIP) Study Group Principal Investigators;.Guidelines for using verteporfin (Visudyne-) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.Retina 2002;22:6-18
29. Mitchell PR, Korobelnik JF, Lanzetta P, et al.Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials.Br J Ophthalmol 2010;94:2-13
30. Koh A, Lee WK, Chen LJ, et al.EVEREST study: Efficacy and safety of verteporfin PDT in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.Retina 2012;32:1453-1464
31. Ahuja RM, Stanga PE, Vingerling JR, et al.Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments.Br J Ophthalmol 2000;84:479-484
32. Ampornpruet A, Ruamviboonsuk P, Kokekhuntod S.The fundoscopic features for differentiation between polypoidal choroidal vasculopathy and choroidal neovascularization from age-related macular degeneration.J Med Assoc Thai 2005;88:S51-S56
33. Cackett P, Wong D, Yeo I.A classification system for polypoidal choroidal vasculopathy.Retina 2009;29:187-191
34. Cackett P, Htoon H, Wong D, Yeo I.Haemorrhagic pigment epithelial detachment as a predictive feature of polypoidal choroidal vasculopathy in a Chinese population.Eye (Lond) 2010;24:789-792
35. Hassenstein A, Meyer CH.Clinical use and research applications of Heidelberg retinal angiography and spectral-domain optical coherence tomography -A review.Clin Experiment Ophthalmol 2009;37:130-143
36. Hikichi T, Ohtsuka H, Higuchi M, et al.Causes of macular serous retinal detachments in Japanese patients 40 years and older.Retina 2009;29:395-404
37. Hirami Y, Tsujikawa A, Otani A, et al.Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy.Retina 2007;27:335-341
38. Hirami Y, Mandai M, Takahashi M, et al.Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degeneration.Jpn J Ophthalmol 2009;53:396-407
39. Iida T, Yannuzzi LA, Freund KB, et al.Retinal angiopathy and polypoidal choroidal vasculopathy.Retina 2002;22:455-463
40. Jalali S, Parra SL, Majji AB, et al.Ultrasonographic characteristics and treatment outcomes of surgery for vitreous hemorrhage in idiopathic polypoidal choroidal vasculopathy.Am J Ophthalmol 2006;142:608-619
41. Kang SW, Chung SE, Shin WJ, Lee JH.Polypoidal choroidal vasculopathy and late geographic hyperfluorescence on indocyanine green angiography.Br J Ophthalmol 2009;93:759-764
42. Kawasaki R, Yasuda M, Song SJ, et al.The prevalence of agerelated macular degeneration in Asians: A systematic review and meta-Analysis.Ophthalmology 2010;117:921-927
43. Kwok AK, Lai TY, Chan CW, et al.Polypoidal choroidal vasculopathy in Chinese patients.Br J Ophthalmol 2002;86: 892-897
44. Okubo A, Ito M, Sameshima M, et al.Pulsatile blood flow in the polypoidal choroidal vasculopathy.Ophthalmology 2005; 112:1436-1441
45. Okubo A, Hirakawa M, Ito M, et al.Clinical features of early and late stage polypoidal choroidal vasculopathy characterized by lesion size and disease duration.Graefes Arch Clin Exp Ophthalmol 2008;246:491-499
46. Rosen RB, Hathaway M, Rogers J, et al.Simultaneous OCT/ SLO/ICG imaging.Invest Ophthalmol Vis Sci 2009;50: 851-860
47. Sa HS, Cho HY, Kang SW.Optical coherence tomography of idiopathic polypoidal choroidal vasculopathy.Korean J Ophthalmol 2005;19:275-280
48. Song SJ, Youm DJ, Chang Y, Yu HG.Age-related macular degeneration in a screened South Korean population: Prevalence, risk factors, and subtypes.Ophthalmic Epidemiol 2009;16:304-310
49. Spaide RF, Yannuzzi LA, Slakter JS, et al.Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.Retina 1995;15:100-110
50. Stanga PE, Lim JI, Hamilton P.Indocyanine green angiography in chorioretinal diseases: Indications and interpretation: An evidence-based update.Ophthalmology 2003;110:15-21
51. Ueta T, Obata R, Inoue Y, et al.Background comparison of typical age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.Ophthalmology 2009;116:2400-2406
52. Wen F, Chen C, Wu D, Li H.Polypoidal choroidal vasculopathy in elderly Chinese patients.Graefes Arch Clin Exp Ophthalmol 2004;242:625-629
53. Yannuzzi LA, Freund KB, Goldbaum M, et al.Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy.Ophthalmology 2000;107:767-777
54. Yasuno Y, Miura M, Kawana K, et al.Visualization of subretinal pigment epithelium morphologies of exudative macular diseases by high-penetration optical coherence tomography.Invest Ophthalmol Vis Sci 2009;50:405-413
55. Akaza E, Yuzawa M, Matsumoto Y, et al.Role of photodynamic therapy in polypoidal choroidal vasculopathy.Jpn J Ophthalmol 2007;51:270-277
56. Akaza E, Mori R, Yuzawa M.Long-Term results of photodynamic therapy of polypoidal choroidal vasculopathy.Retina 2008;28:717-722
57. Byeon SH, Lew YJ, Lee SC, Kwon OW.Clinical features and follow-up results of pulsating polypoidal choroidal vasculop-Athy treated with photodynamic therapy.Acta Ophthalmol 2010;88:660-668
58. Chan WM, Lam DS, Lai TY, et al.Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series.Ophthalmology 2004;111:1576-1584
59. Eandi CM, Ober MD, Freund KB, et al.Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.Retina 2007;27:825-831
60. Gomi F, Sawa M, Mitarai K, et al.Angiographic lesion of polypoidal choroidal vasculopathy on indocyanine green and fluorescein angiography.Graefes Arch Clin Exp Ophthalmol 2007;245:1421-1427
61. Gomi F, Ohji M, Sayanagi K, et al.One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.Ophthalmology 2008;115:141-146
62. Gomi F, Sawa M, Sakaguchi H, et al.Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy.Br J Ophthalmol 2008;92:70-73
63. Hayashi H, Yamashiro K, Tsujikawa A, et al.Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration.Am J Ophthalmol 2009;148:83-89
64. Helbig H, Niederberger H, Valmaggia C, Bischoff P.Simultaneous fluorescein and indocyanine green angiography for exudative macular degeneration.Klin Monbl Augenheilkd 2005;222:202-205
65. Honda S, Imai H, Yamashiro K, et al.Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A multicenter study in Hyogo prefecture, Japan.Ophthalmologica 2009;223:333-338
66. Honda S, Kurimoto Y, Kagotani Y, et al.Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A 30-month multicenter study in Hyogo, Japan.Jpn J Ophthalmol 2009;53:593-597
67. Hussain N, Hussain A, Natarajan S.Role of photodynamic therapy in polypoidal choroidal vasculopathy.Indian J Ophthalmol 2005;53:101-104
68. Kokame GT, Yeung L, Lai JC.Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results.Br J Ophthalmol 2010;94:297-301
69. Kurashige Y, Otani A, Sasahara M, et al.Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.Am J Ophthalmol 2008;146:513-519
70. Lai TY, Chan WM, Liu DT, et al.Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.Br J Ophthalmol 2008;92:661-666
71. Lai TY, Lam CP, Luk FO, et al.Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy.J Ocul Pharmacol Ther 2010;26:91-95
72. Lee MW, Yeo I, Wong D, Ang CL.Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy.Eye (Lond) 2009;23:1417-1422
73. Lee SC, Seong YS, Kim SS, et al.Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula.Ophthalmologica 2004;218:193-201
74. Lee SY, Kim JG, Joe SG, et al.The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.Korean J Ophthalmol 2008;22:92-99
75. Lee WK, Lee PY, Lee SK.Photodynamic therapy for polypoidal choroidal vasculopathy: Vaso-occlusive effect on the branching vascular network and origin of recurrence.Jpn J Ophthalmol 2008;52:108-115
76. Lim JY, Lee SY, Kim JG, et al.Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.Acta Ophthalmol 2012;90:61-67
77. Mauget-Faysse M, Mimoun G, Ruiz-Moreno JM, et al.Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis.Retina 2006;26:396-403
78. Mitamura Y, Kubota-Taniai M, Okada K, et al.Comparison of photodynamic therapy to transpupillary thermotherapy for polypoidal choroidal vasculopathy.Eye (Lond) 2009;23:67-72
79. Moorthy RS, Lyon AT, Rabb MF, et al.Idiopathic polypoidal choroidal vasculopathy of the macula.Ophthalmology 1998; 105:1380-1385
80. Ogino T, Takeda M, Imaizumi H, Okushiba U.Photodynamic therapy for age-related macular degeneration in Japanese patients: Results after one year.Jpn J Ophthalmol 2007;51: 210-215
81. Otani A, Sasahara M, Yodoi Y, et al.Indocyanine green angiography: Guided photodynamic therapy for polypoidal choroidal vasculopathy.Am J Ophthalmol 2007;144:7-14
82. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, et al.Short-Term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy.Eur J Ophthalmol 2008;18:645-648
83. Saito M, Iida T, Nagayama D.Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: Comparison of the presence of serous retinal pigment epithelial detachment.Br J Ophthalmol 2008;92:1642-1647
84. Sasahara M, Tsujikawa A, Musashi K, et al.Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability.Am J Ophthalmol 2006;142:601-607
85. Sato T, Kishi S, Matsumoto H, Mukai R.Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.Am J Ophthalmol 2010;149:947-954
86. Shima C, Gomi F, Sawa M, et al.One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration.Graefes Arch Clin Exp Ophthalmol 2009;247:899-906
87. Silva RM, Figueira J, Cachulo ML, et al.Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.Graefes Arch Clin Exp Ophthalmol 2005;243:973-979
88. Song JH, Byeon SH, Lee SC, et al.Short-Term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy.Ophthalmologica 2009;223:85-92
89. Spaide RF, Donsoff I, Lam DL, et al.Treatment of polypoidal choroidal vasculopathy with photodynamic therapy.Retina 2002;22:529-535
90. Tamura H, Tsujikawa A, Otani A, et al.Polypoidal choroidal vasculopathy appearing as classic choroidal neovascularisation on fluorescein angiography.Br J Ophthalmol 2007;91: 1152-1159
91. Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H.Two year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions.Retina 2009;29:960-965
92. Wakabayashi T, Gomi F, Sawa M, et al.Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy.Br J Ophthalmol 2008;92:936-940
93. Windisch R, Windisch BK, Cruess AF.Use of fluorescein and indocyanine green angiography in polypoidal choroidal vasculopathy patients following photodynamic therapy.Can J Ophthalmol 2008;43:678-682
94. Yamashiro K, Tsujikawa A, Nishida A, et al.Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.Jpn J Ophthalmol 2008;52:457-462
95. Yamashita A, Shiraga F, Shiragami C, et al.One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.Am J Ophthalmol 2010;149:465-471
96. Yuzawa M, Mori R, Haruyama M.A study of laser photocoagulation for polypoidal choroidal vasculopathy.Jpn J Ophthalmol 2003;47:379-384
97. Yuzawa M, Mori R, Kawamura A.The origins of polypoidal choroidal vasculopathy.Br J Ophthalmol 2005;89:602-607
98. Imasawa M, Sakurada Y, Iijima H.Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy.Jpn J Ophthalmol 2011;55:241-247
99. Chae JB, Lee JY, Yang SJ, et al.Time-lag between subretinal fluid and pigment epithelial detachment reduction after polypoidal choroidal vasculopathy treatment.Korean J Ophthalmol 2011;25:98-104
100. Matsumiya W, Honda S, Bessho H, et al.Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.J Ophthalmol 2011;2011:742020
101. Song MH, Ryu HW, Roh YJ.One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Ophthalmologica 2011;226: 119-126
102. Kim KS, Lee WK.Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy.Jpn J Ophthalmol 2011;55:370-377
103. Mitamura Y, Kitahashi M, Kubota-Taniai M, Yamamoto S.Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-Term results.Indian J Ophthalmol 2010;58:291-296
104. Coppens G, Spielberg L, Leys A.Polypoidal choroidal vasculopathy, diagnosis and management.Bull Soc Belge Ophtalmol 2011;39-44
105. de Crecchio G, Chan RV, Manzi G, Romano MR.Polypoidal choroidal vasculopathy: Recent advances in therapy.Curr Drug Targets 2011;12:206-211
106. Wakabayashi T, Gomi F, Sawa M, et al.Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.Br J Ophthalmol 2012;96: 394-399
107. Shah AM, Bressler NM, Jampol LM.Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol 2011;152:332-339
108. Hikichi T, Ohtsuka H, Higuchi M, et al.Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.Am J Ophthalmol 2010;150:674-682
109. Akaza E, Yuzawa M, Mori R.Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.Jpn J Ophthalmol 2011;55:39-44
110. Bessho H, Honda S, Kondo N, Negi A.The association of agerelated maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Mol Vis 2011;17:977-982
111. Cheng CK, Peng CH, Chang CK, et al.One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.Retina 2011;31:846-856
112. Cho M, Barbazetto IA, Freund KB.Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.Am J Ophthalmol 2009;148:70-78
113. Gomi F, Sawa M, Wakabayashi T, et al.Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.Am J Ophthalmol 2010;150:48-54
114. Husain D, Kim I, Gauthier D, et al.Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.Arch Ophthalmol 2005;123:509-516
115. Imasawa M, Tsumura T, Sekine A, et al.Photodynamic therapy for polypoidal choroidal vasculopathy: Baseline perimetric results and visual outcomes.Jpn J Ophthalmol 2009;53:588-592
116. Kim M, Kim K, Kim dG, et al.Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.Ophthalmologica 2011;226:205-213
117. Kim SJ, Yu HG.Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.Retina 2011;31:1827-1834
118. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S.Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy.Br J Ophthalmol 2011;95:1555-1559
119. Lai TY, Lee GK, Luk FO, Lam DS.Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.Retina 2011;31:1581-1588
120. Leal S, Silva R, Figueira J, et al.Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: Results after 3 years of follow-up.Retina 2010;30:1197-1205
121. Lee MW, Yeo I, Wong D, Ang CL.Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy.Eye (Lond) 2009;23:145-148
122. Lee YH, Lee EK, Shin KS, et al.Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.Retina 2011;31:1287-1293
123. Maruko I, Iida T, Sugano Y, et al.Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.Am J Ophthalmol 2011;151:594-603
124. Mauget-Faysse M, Quaranta-El Maftouhi M, De La ME, Leys A.Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.Eur J Ophthalmol 2006;16:695-704
125. Moon SW, Kim MS, Kim ES, et al.Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.Ophthalmologica 2011;225:169-175
126. Mori R, Yuzawa M, Lee Z, et al.Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.Graefes Arch Clin Exp Ophthalmol 2010;248:1233-1239
127. Nakata I, Yamashiro K, Yamada R, et al.Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy.Ophthalmology 2011;118:1408-1415
128. Nishijima K, Takahashi M, Akita J, et al.Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy.Am J Ophthalmol 2004;137:770-773
129. Oishi A, Mandai M, Kimakura M, et al.Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy.Eye (Lond) 2011;25: 1020-1026
130. Romano MR, Cipollone U, Semeraro F, et al.Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: One-year follow-up.Clin Ophthalmol 2010;4:1237-1241
131. Rouvas AA, Papakostas TD, Ntouraki A, et al.Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.Retina 2011;31:464-474
132. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, et al.Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: Results of a 1-year preliminary study.Br J Ophthalmol 2010;94:1045-1051
133. Saito M, Iida T, Kano M.Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.Retina 2011;31:1589-1597
134. Sakurada Y, Kubota T, Imasawa M, et al.Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy.Retina 2010;30:1616-1621
135. Tomita K, Tsujikawa A, Yamashiro K, et al.Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.Am J Ophthalmol 2012;153:68-80.e1
136. Tsujikawa A, Ooto S, Yamashiro K, et al.Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.Jpn J Ophthalmol 2010;54:310-319
137. Sagong M, Lim S, Chang W.Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.Am J Ophthalmol 2012; 153:873-882.e2
138. Ricci F, Calabrese A, Regine F, et al.Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.Retina 2012;32: 1280-1288
139. Cho HJ, Kim JW, Lee DW, et al.Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy.Eye (Lond) 2012;26:426-433
140. Park DH, Kim IT.LOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy.Retina 2012;32:299-307
141. Saito M, Iida T, Nagayama D.Cross-sectional and en face optical coherence tomographic features of polypoidal choroidal vasculopathy.Retina 2008;28:459-464
142. Khan S, Engelbert M, Imamura Y, Freund KB.Polypoidal choroidal vasculopathy: Simultaneous indocyanine green angiography and eye-Tracked spectral domain optical coherence tomography findings.Retina 2012;32:1057-1068
143. Lafaut BA, Aisenbrey S, Van den BC, et al.Polypoidal choroidal vasculopathy pattern in age-related macular degeneration: A clinicopathologic correlation.Retina 2000;20:650-654
144. Desmettre T, Devoisselle JM, Mordon S.Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography.Surv Ophthalmol 2000;45:15-27
145. Lafaut BA, Bartz-Schmidt KU, Vanden Broecke C, et al.Clinicopathological correlation in exudative age related macular degeneration: Histological differentiation between classic and occult choroidal neovascularisation.Br J Ophthalmol 2000;84:239-243
146. Lafaut BA, Aisenbrey S, Vanden Broecke C, Bartz-Schmidt KU.Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration.Br J Ophthalmol 2000;84:1269-1274
147. Iranmanesh R, Eandi CM, Peiretti E, et al.The nature and frequency of neovascular age-related macular degeneration.Eur J Ophthalmol 2007;17:75-83
148. Tsujikawa A, Sasahara M, Otani A, et al.Pigment epithelial detachment in polypoidal choroidal vasculopathy.Am J Ophthalmol 2007;143:102-111
149. Japanese Study Group of Polypoidal Choroidal Vasculopathy.[Criteria for diagnosis of polypoidal choroidal vasculopathy].Nippon Ganka Gakkai Zasshi 2005;109:417-427
150. Ahuja RM, Stanga PE, Vingerling JR, et al.Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments.Br J Ophthalmol 2000;84:479-484
151. Yoon JS, Lee J, Lee SC, et al.Polypoidal choroidal vasculopathy in Korean patients with large submacular hemorrhage.Yonsei Med J 2007;48:225-232
152. Brown DM, Michels M, Kaiser PK, et al.Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.Ophthalmology 2009;116:57-65
153. Lux A, Llacer H, Heussen FM, Joussen AM.Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions.Br J Ophthalmol 2007;91:1318-1322
154. Stangos AN, Gandhi JS, Nair-Sahni J, et al.Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.Am J Ophthalmol 2010;150:666-673
155. Ojima Y, Hangai M, Sakamoto A, et al.Improved visualization of polypoidal choroidal vasculopathy lesions using spectraldomain optical coherence tomography.Retina 2009;29:52-59
156. Tateiwa H, Kuroiwa S, Gaun S, et al.Polypoidal choroidal vasculopathy with large vascular network.Graefes Arch Clin Exp Ophthalmol 2002;240:354-361
157. Costa RA, Navajas EV, Farah ME, et al.Polypoidal choroidal vasculopathy: Angiographic characterization of the network vascular elements and a new treatment paradigm.Prog Retin Eye Res 2005;24:560-586
158. Phillips WB, Regillo CD, Maguire JI.Indocyanine green angiography of idiopathic polypoidal choroidal vasculopathy.Ophthalmic Surg Lasers 1996;27:467-470
159. Akaza E, Matsumoto Y, Yuzawa M.[Pulsation in polypoidal choroidal vasculopathy].Nippon Ganka Gakkai Zasshi 2006; 110:288-292
160. Watanabe G, Fujii H, Kishi S.Imaging of choroidal hemodynamics in eyes with polypoidal choroidal vasculopathy using laser speckle phenomenon.Jpn J Ophthalmol 2008;52:175-181
161. Chan WM, Liu DT, Lai TY, et al.Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: A pilot study of one-year follow up.Clin Experiment Ophthalmol 2005;33:611-618
162. Chang AA, Zhu M, Billson F.The interaction of indocyanine green with human retinal pigment epithelium.Invest Ophthalmol Vis Sci 2005;46:1463-1467
163. Yamaoka S, Okada AA, Sugahara M, Hida T.Clinical features of polypoidal choroidal vasculopathy and visual outcomes in the absence of classic choroidal neovascularization.Ophthalmologica 2010;224:147-152
164. Laude A, Cackett PD, Vithana EN, et al.Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease? Prog Retin Eye Res 2010;29:19-29
165. Kaiser PK, Boyer DS, Cruess AF, et al.Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study.Ophthalmology 2012;119:1001-1010
166. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al.Verteporfin plus ranibizumab for choroidal neovascularization in agerelated macular degeneration: Twelve-month MONT BLANC study results.Ophthalmology 2012;119:992-1000
167. Machida S, Nishimura T, Tamada K, et al.Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy.Doc Ophthalmol 2012;124:91-98
168. Brown DM, Kaiser PK, Michels M, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration.N Engl J Med 2006;355:1432-1444
169. Rosenfeld PJ, Brown DM, Heier JS, et al.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med 2006;355:1419-1431
170. Lowe J, Araujo J, Yang J, et al.Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.Exp Eye Res 2007;85:425-430
171. Matsuoka M, Ogata N, Otsuji T, et al.Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy.Br J Ophthalmol 2004;88:809-815
172. Tong JP, Chan WM, Liu DT, et al.Aqueous humor levels of vascular endothelial growth factor and pigment epitheliumderived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.Am J Ophthalmol 2006;141:456-462
173. Heier JS, Antoszyk AN, Pavan PR, et al.Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study.Ophthalmology 2006;113:633-634
174. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N.Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.Ophthalmology 2006;113:623-632
175. Visudyne- (Verteporfin) Summary of Product Characteristics.Horsham, West Sussex, UK: Novartis Europharm Ltd; 2007
176. Kim A, Gomi F, Sakaguchi H, et al.[Sub-Tenon's injection of triamcinolone acetonide for choroidal neovascularization].Nippon Ganka Gakkai Zasshi 2006;110:19-24
177. Okubo A, Ito M, Kamisasanuki T, Sakamoto T.Visual improvement following trans-Tenon's retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy.Graefes Arch Clin Exp Ophthalmol 2005;243:837-839
178. Lucentis- (Ranibizumab) Summary of Product Characteristics.Basel, Switzerland: Novartis Pharma AG; 2008